Published on 02/12/2025

Biologics & ATMPs: CPV Considerations

Introduction to Continued Process Verification (CPV)

In the context of biologics and advanced therapy medicinal products (ATMPs), Continued Process Verification (CPV) represents a critical approach for ensuring quality and consistency post-commercialization. CPV is an integral part of the regulatory expectations set forth by agencies such as the FDA and the European Medicines Agency (EMA), particularly in achieving compliance with standards established in guidelines like EU GMP Annex 15 and 21 CFR Part 11.

The transition from traditional process validation to CPV requires a comprehensive understanding of various intertwining factors, including statistical process control, risk management principles as per ICH Q9, and a solid grasp of the FDA process validation requirements. This section will outline the foundation on which CPV is established, emphasizing the importance of a well-structured approach to managing and monitoring an ongoing manufacturing process.

The Regulatory Landscape of CPV

Understanding the regulatory frameworks surrounding CPV is paramount for pharmaceutical professionals involved in process validation for biologics and ATMPs. The guidelines issued by regulatory authorities, particularly the European Medicines Agency (EMA) and the International Council for Harmonisation (ICH), underscore the necessity of ensuring a proactive approach towards quality assurance during a product’s lifecycle.

CPV serves not only as a regulatory requirement but also as a vital tool to demonstrate that the manufacturing process remains in a state of control, yielding products that consistently meet predefined quality attributes. According to EU GMP Annex 15, the CPV system should be integrated into the quality management system and should include procedures for monitoring manufacturing processes and evaluating the results.

The following are essential guidelines to follow when implementing CPV:

• Establish a CPV plan: Focus on defining the quality attributes critical to the product’s efficacy and safety.
• Process performance metrics: Utilize statistical methods to define and utilize performance metrics that indicate whether the process remains in control.
• Regular assessment and documentation: Consistently document and evaluate process data to track performance trends over time.

Developing a Continued Process Verification Strategy

A robust CPV strategy is essential for maintaining the quality of biologics and ATMPs. Developing this strategy involves several steps that guide the implementation of effective CPV practices.

Step 1: Risk Assessment and Quality Attribute Definition

Risk assessment is the first crucial step in CPV development. Utilizing the principles of ICH Q9 risk management, pharmaceutical professionals should identify and evaluate potential risks in manufacturing processes. An effective risk assessment helps in determining the quality attributes that are most critical to the product’s performance.

Alternatively, Quality by Design (QbD) principles can be applied to define acceptable ranges for these critical quality attributes (CQAs). CQAs may include factors such as potency, purity, stability, and bioavailability—all of which need to be continuously monitored throughout the product lifecycle.

Step 2: Establishing a Continued Process Verification Framework

The next step in developing a CPV strategy involves creating a framework that will facilitate continuous assessment of product quality. This CPV framework should include well-defined processes for:

• Data collection: Identify sources of data, both from manufacturing processes and from quality control testing.
• Statistical analysis: Employ various statistical tools to analyze data trends over time, identifying potential deviations from expected performance.
• Change control systems: Integrate a process for documenting and evaluating changes in the manufacturing process and their impacts on product quality.

Step 3: Developing the CPV Sampling Plan

A continued process verification sampling plan is fundamental for acquiring representative data over time. The plan must outline:

• Sampling frequency: Determining how often samples will be taken based on risk assessment outcomes, historical data, and specific monitoring objectives.
• Sampling methodology: Ensuring that samples are collected in a manner that reflects the entire production batch and minimizes bias.
• Acceptance criteria: Establishing clear thresholds within which the process must operate, ensuring ongoing compliance with product specifications.

The sampling plan should be capable of adjusting to variations in production scaling, especially relevant for ATMPs where production conditions may change significantly over time.

Implementation and Documentation of CPV Activities

Successful CPV implementation requires systematic recording and documentation of activities at every stage of the process verification.

Step 1: Data Collection and Analysis

Utilize automated data collection systems where feasible, to capture both manufacturing and quality control data in real time. This information should be processed and analyzed using statistical methods to identify trends and deviations. Continuous data review enables timely corrections and process adjustments to maintain product quality.

Charting tools, control charts, and statistical software can facilitate trend analysis, providing crucial insights into the manufacturing process’s performance. Key performance indicators (KPIs) should also be established to aid in ongoing assessment.

Step 2: Reporting and Review

Regularly review and report the findings from CPV activities to all relevant stakeholders. A structured report should summarize deviations, interventions, and improvements made during the production process. Efforts in deviation investigation should emphasize root cause analysis, with resultant corrective and preventative actions documented as part of the process.

Periodic reviews, typically conducted quarterly or biannually, can help identify persistent issues and drive continuous improvements in CPV activities.

Step 3: Integration into Quality Management Systems

The CPV framework must be properly integrated into the existing quality management system (QMS) to be effective. Documentation policies should be aligned with regulatory requirements, including compliance with 21 CFR Part 11 concerning electronic records and signatures. This regulation emphasizes the importance of maintaining data integrity and security.

Critical Considerations for CPV in Biologics and ATMPs

Implementing CPV in the context of biologics and ATMPs presents unique challenges due to the complex nature of these products. The following considerations are critical for successful CPV implementation:

• Regulatory changes: Stay abreast of evolving regulatory expectations to ensure compliance with both FDA and EMA guidelines relating to biologics and ATMPs.
• Product complexity: Recognize and adapt CPV measures to account for the inherent variability associated with biologics and ATMPs, necessitating a flexible approach to sampling and monitoring.
• Technology transfer: Ensure that CPV strategies address the implications of technology transfer, particularly as it relates to scale-up challenges and maintaining process control during the transition.

Conclusion: The Path Forward for Continuous Process Verification

Continued process verification is not just a regulatory expectation but a necessary ethos within the pharmaceutical industry, especially for biologics and ATMPs. By embracing the principles outlined in this guide, pharmaceutical professionals can foster a culture of safety, quality, and continuous improvement.

As manufacturing technologies and regulatory landscapes evolve, so must the CPV strategies employed within the industry. Focused collaboration, ongoing training, and a commitment to quality will facilitate the successful implementation of CPV practices, ultimately assuring product safety and efficacy in the marketplace.

By applying structured methodologies for CPV and adhering to the established guidelines, organizations can anticipate challenges, adapt swiftly to changes, and assure compliance with both FDA and EMA requirements for biologics and ATMPs.